← All themes

Immunotherapy & Oncology

Cancer treatment has moved from poisoning dividing cells towards directing the immune system at the tumour, and towards drugs that carry their payload only to cancerous tissue. It absorbs more drug development spending than any other area.

388 stocks

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Johnson & Johnson JNJ $611B	3,813	-46	-1%	$249B
2	2 Merck MRK $365B	3,553	+8	+0.2%	$242B
3	3 AbbVie ABBV $506B	3,372	-16	-0.5%	$217B
4	4 Pfizer PFE $169B	2,881	-2	-0.1%	$105B
5	5 Amgen AMGN $238B	2,791	+69	+3%	$129B
6	6 Bristol-Myers Squibb BMY $125B	2,155	-184	-8%	$63.8B
7	7 Gilead Sciences GILD $198B	1,681	-43	-2%	$71.3B
8	8 Regeneron Pharmaceuticals REGN $82.6B	1,335	+23	+2%	$98.9B
9	9 Novartis NVS $287B	1,308	+53	+4%	$14.7B
10	10 AstraZeneca AZN $259B	1,213	+70	+6%	$39B
11	11 GSK GSK $98.6B	886	-26	-3%	$12B
12	12 Incyte INCY $23.1B	585	-2	-0.3%	$12B
13	13 DELISTED Exact Sciences EXAS	545	-82	-13%	$7.57B
14	14 Natera NTRA $58.1B	475	+62	+15%	$13.1B
15	15 Halozyme HALO $13.8B	460	+46	+11%	$6.4B
16	16 Jazz Pharmaceuticals JAZZ $13.9B	457	-24	-5%	$6.14B
17	17 Lantheus LNTH $6.53B	452	+42	+10%	$5.48B
18	18 Exelixis EXEL $15.5B	415	-7	-2%	$5.47B
19	19 Qiagen QGEN $9.56B	306	+23	+8%	$6.22B
20	20 DELISTED Blueprint Medicines BPMC	305	+23	+8%	$7.15B
21	21 Iovance Biotherapeutics IOVA $6.48B	295	+22	+8%	$1.86B
22	22 BioNTech BNTX $22.7B	286	-1	-0.3%	$3.3B
23	23 Takeda Pharmaceutical TAK $62.7B	285	-30	-10%	$1.15B
24	24 Guardant Health GH $22.3B	282	+24	+9%	$3.32B
25	25 Recursion Pharmaceuticals RXRX $2.28B	270	+21	+8%	$1.89B